Nasdaq
$3.56▲ 0.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $128.2MShares out 36.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.13After-hours26.10.14 06:134Ownership#●●●
AN2 Therapeutics, Inc.
Insider Gilbert Lynn Marks of AN2 Therapeutics, Inc. filed a Form 4 on October 13, 2026, reporting a change in beneficial ownership of securities as of October 12, 2026.…more
$3.56+0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 06:124Ownership
AN2 Therapeutics, Inc.
Insider Patricia A. Martin of AN2 Therapeutics, Inc. reported a change in beneficial ownership of securities as of October 12, 2026. This filing provides details regarding the insider's equity transaction.…more
$3.56+0.14%vs prev closeView filingShare - 10.13After-hours26.10.14 06:124Ownership
AN2 Therapeutics, Inc.
Insider Aziz Kabeer of AN2 Therapeutics, Inc. reported a change in beneficial ownership of securities effective October 12, 2026. This filing formalizes the insider's transaction details via Form 4.…more
$3.56+0.14%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:07#●●●#●●●#●●●
AN2 Therapeutics to Present Phase 2 Trial Design for Epetraborole on Oct 29…more
AN2 Therapeutics is scheduled to present its planned Phase 2 trial design for epetraborole in treating polycythemia vera on October 29. As this is an announcement of trial design rather than clinical results, the impact remains to be seen.…more
$3.56+0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.28Pre-market26.09.28 20:02
●●●●●●●● ●●●●● ●●●●●●
AN2 Therapeutics has received additional funding from the Bill & Melinda Gates Foundation to continue its tuberculosis research collaboration with GSK. This extension supports the ongoing development efforts within their existing partnership.…more
$3.56+0.14%vs prev closeShareBenzinga - 8.31After-hours26.09.01 07:06
●●●●●●●● ●●●●● ●●●●●●
AN2 Therapeutics will present four abstracts featuring clinical and nonclinical data for its polycythemia vera treatment candidate, epetraborole, at the SOHO 2026 Annual Meeting. These findings are intended to support the ongoing development of the company's novel oral therapeutic.…more
$3.56+0.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report